Companion Animal Drugs Market to cross USD 51.1 billion by 2035

The global companion animal drugs market was valued at USD 26.8 billion in 2025. The market is expected to grow from USD 28.8 billion in 2026 to USD 51.1 billion in 2035, growing at a CAGR of 6.6% during the forecast period, according to the latest report published by Global Market Insights Inc.

Rising Companion Animal Population

The growing companion animal population has emerged as a significant factor supporting the expansion of the animal healthcare industry. Increasing pet ownership across both developed and developing regions has been driven by changing lifestyles, urbanization, and a stronger emotional bond between people and their pets. Many households have increasingly viewed pets as family members, resulting in greater attention to their overall health and well-being.

Increasing Prevalence of Animal Diseases

The rising incidence of infectious, parasitic, and chronic diseases among both livestock and companion animals has significantly increased the need for effective animal healthcare solutions. Factors such as growing animal populations, increased movement of animals across regions, changing environmental conditions, and evolving disease patterns have contributed to a higher risk of disease outbreaks.

High Cost of Veterinary Drugs and Treatments

The high cost of veterinary drugs and treatment procedures has remained a significant challenge for the animal healthcare industry. Advanced medications, specialized therapies, diagnostic services, and surgical interventions often involve substantial expenses, which can limit access to comprehensive veterinary care for some animal owners. The development of innovative veterinary pharmaceuticals requires extensive research, clinical testing, regulatory approvals, and manufacturing investments, all of which contribute to higher product costs.

Browse key industry insights spread across 148 pages with 250 market data tables and figures from the report, Companion Animal Drugs Market, “By Product (Drugs, Vaccines, Medicated Feed Additives), By Animal Type (Dogs, Cats, Horses, Other Animal Types), By Indication (Dermatology, Cardiovascular Diseases, Gastrointestinal Diseases, Respiratory Diseases, Other Indications), By Route of Administration (Oral, Injectable, Topical, Other Routes of Administration), and By Distribution Channel (Veterinary Hospital Pharmacies, E-commerce, Retail Pharmacies).” in detail, along with the table of contents: https://www.gminsights.com/industry-analysis/companion-animal-drugs-market

Increasing Adoption of the Drugs

In 2025, the drugs segment generated USD 17.1 billion in the companion animal drugs market. The segment maintained a leading position due to the growing incidence of long-term health conditions and infectious diseases among companion animals. Increasing cases of joint disorders, oncology-related conditions, dermatological issues, and other chronic ailments continued to create substantial demand for veterinary pharmaceuticals.

Rising Use in Dermatology

The dermatology segment held a dominant share of the companion animal drugs market in 2025 and is projected to reach USD 17 billion by 2035. Growth in this segment was primarily supported by the increasing occurrence of skin-related disorders in companion animals. Conditions associated with allergies, external parasites, and microbial infections continued to drive demand for specialized dermatological treatments.

North America to Emerge as a Propelling Region

North America companion animal drugs market accounted for 42.9% share in 2025 and is expected to grow at a CAGR of 6.3% during 2026-2035. The region maintained its leadership position due to a large companion animal population, advanced veterinary healthcare infrastructure, and strong expenditure on animal wellness. Growing awareness regarding preventive healthcare and increasing willingness among pet owners to invest in advanced treatment solutions continued to support market expansion. The presence of established veterinary networks, widespread access to specialized treatments, and ongoing advancements in animal healthcare further reinforced the region’s dominant market position.

Prominent participants in the companion animal drugs industry included Agrolabo, Boehringer Ingelheim International, Ceva Santé Animale, Chanelle Pharma, Dechra Pharmaceuticals, Elanco Animal Health Incorporated, Endovac Animal Health, HIPRA, Indian Immunologicals, Merck, Norbrook, Symrise, Vetoquinol, Virbac, and Zoetis.

Companies operating in the companion animal drugs market focused on several strategic initiatives to enhance their competitive position and expand market presence. Significant investments in research and development remained a primary strategy, enabling the introduction of innovative therapies, improved formulations, and advanced treatment options for companion animals. Market participants also emphasized product portfolio expansion through new product launches and regulatory approvals to address a wider range of animal health conditions.

In February 2025, Virbac announced the European launch of Vikaly which became the world's first medicated cat food to combine a renal nutrition formula with a veterinary medicine approved through a marketing authorization process.